← Leaderboards
John G. Gribben
Dana-Farber Cancer Institute
$4,031,248
Attributed
$4,031,248
Total exposure
8
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $344K · FY2006–16$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$4,031,248 · 8
By mechanism
P01$4,031,248 · 8
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Margaret A Shipp$7,796,368
- Ellis L Reinherz$59,058,313
- David B. Miklos$5,009,214
Others in their field
Top investigators on “Tumor Antigens”
- William R Green · Dartmouth College$32,738,211
- John H Sampson · Duke University$30,849,602
- Catherine Ju-Ying Wu · Broad Institute, Inc.$30,485,072
- Elizabeth Marion Jaffee · Johns Hopkins University$26,862,085
- Ian M Thompson · University Of Texas Hlth Sci Ctr San Ant$24,066,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Research focus
Tumor AntigensChronic Lymphocytic LeukemiaLeukemiaImmune SystemHuman SubjectImmune ResponseGene ExpressionEtiologyCell Mediated Immune ResponseFutureClinical TrialsImmuneDefectImmune FunctionDonor Lymphocyte InfusionCancer CellBaseAllogenicImmune ToleranceCell PhysiologyAntigen-Presenting CellsCellsIn VivoMalignant Neoplasms
Grant awards (27)
Immune Tolerance and Stem Cell Transplantation$197,537
P01 · FY2016 · CA · contact PI
Immune Tolerance and Stem Cell Transplantation$242,290
P01 · FY2015 · CA · contact PI
Immune Tolerance and Stem Cell Transplantation$239,893
P01 · FY2014 · CA · contact PI
Immune Tolerance and Stem Cell Transplantation$224,131
P01 · FY2013 · CA · contact PI
Immune Tolerance and Stem Cell Transplantation$253,601
P01 · FY2012 · CA · contact PI
Immune Tolerance of CLL Antigens$343,993
P01 · FY2010 · CA · contact PI
Immune Tolerance of CLL Antigens$337,175
P01 · FY2009 · CA · contact PI
Immune Tolerance of CLL Antigens$318,208
P01 · FY2008 · CA · contact PI
Immune Tolerance of CLL Antigens$315,051
P01 · FY2007 · CA · contact PI
Immune Tolerance of CLL Antigens$231,868
P01 · FY2006 · CA · contact PI
Immunology of CLL II adoptive immunotherapy$165,355
P01 · FY2002 · CA
CORE--MOLECULAR BIOLOGY AND IMMUNE ASSESSMENT$109,507
P01 · FY2002 · CA
MOLECULAR MEASUREMENTS OF OUTCOME IN ACUTE LYMPHOCYTIC LEUKEMIA$0
P01 · FY2002 · CA
CORE--CLINICAL TRIALS$0
P01 · FY2002 · CA
Immunology of CLL II adoptive immunotherapy$165,355
P01 · FY2001 · CA
CORE--MOLECULAR BIOLOGY AND IMMUNE ASSESSMENT$109,507
P01 · FY2001 · CA
Immunology of CLL II adoptive immunotherapy$0
P01 · FY2001 · CA
CORE--CLINICAL TRIALS$0
P01 · FY2001 · CA
Immunology of CLL II adoptive immunotherapy$0
P01 · FY2001 · CA
MOLECULAR MEASUREMENTS OF OUTCOME IN ACUTE LYMPHOCYTIC LEUKEMIA$0
P01 · FY2001 · CA
CONTRIBUTION OF RESIDUAL DISEASE &STEM CELL DAMAGE TO CANCER THERAPY OUTCOME$0
P01 · FY2001 · CA
INDUCTION OF HOST SPECIFIC TOLERANCE IN ALLOGENEIC BMT$0
P01 · FY2001 · AI
INDUCTION OF HOST SPECIFIC TOLERANCE IN ALLOGENEIC BMT$276,356
P01 · FY2000 · AI
CORE--MOLECULAR BIOLOGY AND IMMUNE ASSESSMENT$275,287
P01 · FY2000 · CA
CONTRIBUTION OF RESIDUAL DISEASE &STEM CELL DAMAGE TO CANCER THERAPY OUTCOME$226,134
P01 · FY2000 · CA
Immunology of CLL II adoptive immunotherapy$0
P01 · FY2000 · CA
MOLECULAR MEASUREMENTS OF OUTCOME IN ACUTE LYMPHOCYTIC LEUKEMIA$0
P01 · FY2000 · CA